Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540370 | 0.89 | F2 (0.58) | GABRA5GABRB2HSD17B10SMN1; SMN2EGLN1 | |
| SCHEMBL19820647 | 0.87 | HSD17B10 (0.47) | GABRA5GABRB2HSD17B10SMN1; SMN2F2 | |
| SCHEMBL3621586 | 0.87 | GABRA5 (0.55) | GABRA5GABRB2HSD17B10SMN1; SMN2EGLN1 | |
| Hydrochloric Acid SCHEMBL19814023 | 0.86 | HSD17B10 (0.46) | GABRA5GABRB2HSD17B10SMN1; SMN2F2 | |
| Hydrochloric Acid SCHEMBL20640317 | 0.86 | HSD17B10 (0.46) | GABRA5GABRB2HSD17B10SMN1; SMN2F2 | |
| SCHEMBL2111372 | 0.85 | SMN1; SMN2 (0.58) | GABRA5GABRB2HSD17B10SMN1; SMN2LMNA | |
| SCHEMBL14159379 | 0.85 | GABRA5 (0.54) | GABRA5GABRB2HSD17B10SMN1; SMN2EGLN1 | |
| SCHEMBL20640293 | 0.84 | KDM4E (0.51) | GABRA5GABRB2HSD17B10F2F10 | |
| SCHEMBL20649160 | 0.84 | GABRA5 (0.53) | GABRA5GABRB2HSD17B10SMN1; SMN2EGLN1 | |
| Hydrochloric Acid SCHEMBL20640363 | 0.83 | GABRA5 (0.51) | GABRA5GABRB2HSD17B10SMN1; SMN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | disclosed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | disclosed |
| CN-1249039-C | Inhibitors of 11 beta-hydroxysteroid dehydrogenase type I | BIOVITRUM AB (SE) | 2006-04-05 | — | — | CN | disclosed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | disclosed |
| CN-1438997-A | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I | BIOVITRUM AB (SE) | 2003-08-27 | — | — | CN | disclosed |
| EP-1283831-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001090090-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | GABRA5 2105/4885GABRB2 1661/4885HSD17B10 21/4885 |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | GABRA5 2377/4885GABRB2 1435/4885HSD17B10 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.